What is William Blair’s Forecast for Exagen FY2024 Earnings?

Exagen Inc. (NASDAQ:XGN) – Equities researchers at William Blair boosted their FY2024 earnings per share (EPS) estimates for Exagen in a report issued on Wednesday, November 13th. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of ($0.89) for the year, up from their previous forecast of ($0.94). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.87) per share. William Blair also issued estimates for Exagen’s Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.70) EPS.

Exagen Trading Up 2.8 %

Shares of XGN stock opened at $2.98 on Monday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.32 and a current ratio of 4.05. The stock has a fifty day simple moving average of $2.82 and a two-hundred day simple moving average of $2.40. The firm has a market capitalization of $52.57 million, a PE ratio of -3.17 and a beta of 1.35. Exagen has a 52-week low of $1.30 and a 52-week high of $3.71.

Exagen (NASDAQ:XGN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.02. The firm had revenue of $12.51 million for the quarter, compared to analysts’ expectations of $13.55 million. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. During the same quarter in the prior year, the business earned ($0.31) EPS.

Institutional Investors Weigh In On Exagen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Verus Capital Partners LLC bought a new position in Exagen in the third quarter worth approximately $39,000. Creative Planning purchased a new stake in shares of Exagen during the 3rd quarter worth $110,000. Renaissance Technologies LLC raised its stake in shares of Exagen by 93.3% during the 2nd quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock worth $172,000 after acquiring an additional 45,476 shares in the last quarter. Palumbo Wealth Management LLC grew its holdings in Exagen by 14.5% in the third quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock worth $236,000 after purchasing an additional 9,695 shares during the last quarter. Finally, Stonepine Capital Management LLC boosted its position in shares of Exagen by 49.0% in the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after purchasing an additional 175,701 shares in the last quarter. 75.25% of the stock is currently owned by hedge funds and other institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).